Advertisement

P053 IMMUNO-CHECKPOINT INHIBITORS INDUCED COLITIS TREATED WITH MESALAMINE

      Immuno-checkpoint inhibitors (ICI) are becoming an integral part of advanced cancer treatment. ICI-induced colitis (ICI-C) is one of the most common adverse events that is usually treated with steroids, infliximab or vedolizumab. All these agents are immune-suppressants that are associated with certain risks. We describe here an alternative treatment for ICI-C without diminishing ICI effect or causing toxicity.
      To read this article in full you will need to make a payment
      AGA Member Login
      Login with your AGA username and password.
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect